Heron Therapeutics is trading 5.51% down now at $0.32 after investors continued assessing the August 10 earnings miss and withdrawal of full-year 2026 guidance.
- Management cited uncertainty surrounding potential generic competition following a June Delaware patent ruling affecting CINVANTI.
- The company is pausing spending plans and exploring strategic alternatives.
- The broader market is higher on August 13, making company-specific concerns the more likely driver.